Health Rounds: GLP-1 obesity drugs may boost low testosterone
Weight loss from lifestyle changes or bariatric surgery is known to boost testosterone levels, but the impact of anti-obesity medications has not been widely investigated, study leader Dr. Shellsea Portillo Canales of SSM Health St. Louis University Hospital in Missouri said in a statement.
Portillo Canales and colleagues tracked 110 men with obesity – many also with type 2 diabetes – who were being treated with semaglutide, dulaglutide or tirzepatide, the active ingredients in Novo Nordisk's Wegovy and Ozempic or Eli Lilly's Trulicity, Mounjaro, and Zepbound.
The average age was 54. None of the men were receiving other testosterone-boosting medications.
During 18 months of treatment, the proportion of men with testosterone levels in the normal range rose from 53% to 77%.
Testosterone plays a critical role in male sexual functioning but can also impact bone mass, fat distribution, muscle mass, strength and red blood cell production.
In the current study, the greater the weight loss, the greater the improvement in testosterone levels, the researchers found.
While the study cannot prove GLP-1 drugs caused low testosterone levels to normalize, it does show a direct correlation, Portillo Canales noted.
Popular GLP-1 anti-obesity medications are effective for weight loss even when treatment is inconsistent, new findings suggest.
Patients often face challenges in accessing these medications – such as Novo Nordisk's Wegovy and Ozempic and Eli Lilly's Zepbound and Mounjaro - due to supply shortages and insurance coverage obstacles, study leader Kaelen Medeiros of privately held weight-loss company Calibrate in New York said in a statement.
Medeiros and colleagues looked at how interruptions to GLP-1 medication access over the course of two years impacted weight-loss outcomes in 6,392 clients of Calibrate's online metabolic health program. Along with the drugs, the program also included intensive lifestyle interventions and coaching on diet, exercise, sleep and emotional health.
Overall, 72.5% of participants experienced at least one disruption in their GLP-1 treatment and 11.1% had multiple disruptions, Medeiros reported at ENDO 2025.
Participants who faced access issues reported a 13.7% weight loss within 12 months and a 14.9% loss within 24 months, on average. Those without treatment interruptions reported a 17% weight loss in 12 months and 20.1% in 24 months, on average.
Even those who received no more than four treatments over 12 months also achieved clinically significant weight loss, with more than 10% change in body weight on average.
'While unpredictable GLP-1 medication access is frustrating, the good news is that our research shows effective weight loss can still be achieved if paired with appropriate lifestyle changes and coaching support,' Medeiros said.
People who experience a fracture after age 80 might benefit from medications to treat bone deterioration or weakness caused by osteoporosis, researchers reported at the Endocrine Society meeting in San Francisco.
Whether to start osteoporosis drugs at that age has been debated for fear that very elderly patients could be more susceptible to the side effects.
Researchers at the Cleveland Clinic reviewed medical records on 88,676 patients aged 80 and older who had suffered a fracture due to osteoporosis. Half of them had subsequently been treated with either Merck & Co.'s Fosamax, Roche and GlaxoSmithKline's Boniva, Amgen's Prolia, or Eli Lilly's Evista or Forteo.
The others did not receive any osteoporosis drugs.
Over the next five years, after accounting for patients' other health conditions, the hospitalization rate was 19% lower and the mortality rate was 15% lower in the group treated with bone-strengthening medications.
'The results of our study support the need to enhance the individualized initiation of treatment of osteoporosis, even in people who are older than 80,' study leader Dr. Gianina Flocco said in a statement.
'Treating people to reduce the burden of osteoporosis complications, like fractures leading to disability or death, would play a significant role in improving health span in the growing older population.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
2 hours ago
- Reuters
Biogen beefs up North Carolina manufacturing ahead of potential drug tariff storm
July 21 (Reuters) - Biogen (BIIB.O), opens new tab will invest $2 billion more in its existing manufacturing plants in North Carolina, the drugmaker said on Monday, as it seeks to expand in the U.S. amid President Donald Trump's tariff threats. Biogen joins major drugmakers such as Eli Lilly(LLY.N), opens new tab, Roche (ROG.S), opens new tab and Merck, who have all announced investments in the U.S. as the industry braces for potential import levies. Drugs have so far been exempt from Trump's reciprocal tariffs, but he has often argued that separate levies are needed to bolster domestic manufacturing and avoid relying on other countries for medicine supply. Earlier this month, Trump said the tariffs may be delayed, but could be as high as 200%. On Monday, Biogen said it will invest in North Carolina's Research Triangle Park (RTP), the home of its largest manufacturing plants that produce key therapies for multiple sclerosis and Alzheimer's. The investments will expand Biogen's ability to develop and produce certain gene-targeting therapies, and add fill‑finish facilities, automation and artificial intelligence, the company said. The drugmaker has invested about $10 billion in its North Carolina manufacturing to date. It has seven factories in the state with an eighth expected to start working in the second half of 2025.
Telegraph
2 hours ago
- Telegraph
Fat jab makers bet on NHS to be role model for the world
Britain is too fat. One in four people is classed as obese and, on average, they will live nine years less than if they were a healthy weight. They are three times more likely to develop colon cancer and five times more likely to develop type 2 diabetes. Such statistics are not just a crisis in national health, they are also an economic nightmare for the NHS. 'Obesity has doubled since the 1990s and costs our NHS £11bn a year, triple the budget for ambulance services,' Health Secretary Wes Streeting said last month. 'Unless we curb the rising tide of cost and demand, the NHS risks becoming unsustainable.' It is a threat that the Government is taking seriously, with a new ambition to tackle the problem once and for all. 'We now have the science, technology, and knowledge to end the obesity epidemic, if we seize this opportunity,' Streeting says. A crucial part of the plan is the wide rollout of weight-loss injections which, up until this point, have largely been reserved for those who can afford them. The Government instead wants fat jabs to be available 'based on need and not the ability to pay' and is testing new approaches to speed up the rollout of obesity medicines. Public health officials are not the only ones watching closely. At Danish giant Novo Nordisk, which makes obesity jab Wegovy and diabetes drug Ozempic, which can be used off-label for weight loss, executives are eager to know what ministers' next step will be. Sebnem Avsar Tuna, its UK chief, says that the Government's plans could prove a game-changer for Novo Nordisk, showing the benefits of these medicines to the world. 'I think there's a big opportunity for the UK to be a role model,' she says. 'We just need to speed up in terms of getting into the actions, so it's not just on paper ... This is what needs to be shown, at the population health scale, to the entire world: what could be the outcome in a real-world setting.' Test case for the world In other words, Britain could be the test case for the world. If Wegovy can dramatically improve Britain's health – and cut costs – then surely other countries will follow. The Government says it is exploring whether it could bring in a new payment model for weight-loss treatments, so that it would pay pharmaceutical companies based on how well their drugs made the nation healthier. For now, details over the Government's plans remain sparse. The fat jab plans are part of a wider obesity strategy, which also includes curbing calories in supermarkets and getting the country exercising. Ministers have yet to publish a comprehensive strategy. The pharmaceutical industry is not yet clear on which weight-loss drugs could be offered more broadly, nor how they will be rolled out to patients or whether weight limits guiding who can qualify for the jabs will be softened. So far only Eli Lilly's skinny jab Mounjaro is offered on the NHS through GPs. Novo's obesity jab is currently just available through specialist weight management clinics on the public health service, although can be bought privately. Still, both jabs have strict requirements over who is eligible. A person would need to have a BMI of over 40 – classing them as severely obese – as well as at least four of five specific health conditions, which include type 2 diabetes and sleep apnea, to qualify for a weight loss jab when seeking the treatment through a GP. There are concerns that current limits means the drugs are too restricted. 'We should be doing it for people who are becoming obese,' says one government adviser. 'That way, we can get them down to something that looks close to a normal range and then they can go back to work and start paying taxes.' Old habits die hard However, there are concerns that public health officials may resist a broad roll-out of the fat jabs after years where obesity was viewed as a behavioural issue, not something to be treated with medicine. 'The problem is this is very contrary to the status quo in this field, which is: we think you should stop eating, and then you won't be as fat,' the adviser says. There is a 'culture war within the health system between the old school public health doctors who say it's all about behavioural change, and the people who say, 'Hang on a minute, we haven't done so bad with statins, we should do the same with obesity''. 'Wes is probably more inclined to go for the latter view. The trouble is, Wes is not making the decisions. It's being made by a whole load of old-school doctors.' Drug bosses are anxious to see any signs of progress. 'We just need to speed up in terms of getting it done,' says Avsar Tuna. A speedy roll-out could provide not just a boost for Britain's health but also a shot in the arm for Novo Nordisk, which has been struggling in the US. It has faced weaker demand for Wegovy after a boom in cheap replica fat jabs. In May it blamed the copycat drugs – which were allowed by US regulators because of supply issues at Novo Nordisk – for forcing it to slash sales and profit forecasts. Lars Fruergaard Jørgensen was unexpectedly ousted as chief executive at the same time. The arms race in weight loss Regulators have since banned the cheap replicas. Still, it is facing a more existential threat in the form of rival Eli Lilly, amid growing uptake of the US company's Mounjaro weight-loss jab. In a recent head-to-head trial, Mounjaro beat Novo's Wegovy for weight-loss. Barclays analyst Emily Field says she has heard anecdotally that patients prefer Mounjaro too. 'When you look at the side effects in terms of patients that discontinue the drug because they're not feeling well, the two drugs look very similar,' she says. 'But when you actually talk to doctors, they disagree with that. They say that patients just feel better on the Lilly drug.' Novo Nordisk has been racing to develop new medicines to show it can compete, though investors are not entirely convinced. Its share price is down more than 50pc over the past year. Field says the company was 'really hampered' by the fact it was hit by shortages last year. Avsar Tuna says the company has enough capacity to meet demand. 'I can say that we don't have any supply challenges,' she says. If the NHS were to rapidly step up orders, she believes Novo Nordisk could deliver. 'I think it's a positive problem to look at,' Avsar Tuna says. 'If the NHS really comes back and says, tomorrow, I want X number of products from you to be able to give it all to patients, that would be a good dream to have.' Whether the call will come is another matter. Government advisers remain concerned that public health chiefs will try to stand in the way of a sweeping roll-out. 'If you ask me, they're in a bit of a muddle about these drugs,' says one insider. Still, Streeting is clearly convinced that they are the answer to Britain's weight problems. 'This Government is determined to bring revolutionary modern treatments to everyone who needs them, not just those who can afford to pay,' the Health Secretary said last month. 'There can be no doubt that these drugs will support our shift from sickness to prevention and be a game-changer for millions.'
Daily Mail
3 hours ago
- Daily Mail
Mother-of-one reveals the secret to losing a whopping 100lbs in just one year WITHOUT weight-loss jabs
A mother-of-one has revealed how she lost almost 100lbs—seven stone—in less than a year, by sticking to a simple exercise and diet plan. Millions of people now rely on weight loss jabs such as Mounjaro and Wegovy to help them slim down—yet Lucy Weller credits walking 10,000 steps a day and regular weight training sessions with helping her reach her goal. This was coupled with a calorie-controlled diet, high in protein and fibre. In a video shared to TikTok via her page, @lucy52915, which has racked up more than 750,000 views, she revealed pictures of her gradually shedding the pounds. After posting the video, she received over a thousand comments from other social media users amazed by her final transformation. One commentator said: 'Wow! You look unrecognisable, well done. It's so lovely to see it's been done in a healthy way and not on Mounjaro.' Meanwhile another commented: 'You can tell this is natural too. No Mounjaro and excuses here. Well done for creating new habits and not cheating. This will set you up for life. A third user added: 'Incredible. You look like a different person. Great work.' Ms Weller revealed in comment on the viral post that she wasn't able to use jabs—having recently given birth. 'Still breastfeeding my child so can't do Mounjaro anyway, but I have health anxiety so would never do it,' she wrote. Instead she committed to weight training four times a week, with two sessions for glutes—the buttock muscles—one for the full body, and one for the upper body. The weight training sessions she praised for her impressive transformation were with @TrainwithAldine, whom she called 'the best coach there ever is'. In a comment replying, the coach said: 'So proud of you!! Hard work and sticking to the planxxx.' While the mother lost the weight naturally, there are a growing number of people turning to weight loss jabs. Last month, GPs in the UK were allowed to prescribe the drugs, collectively known as GLP-1s, for the first time in a bid to tackle the nation's obesity crisis. An estimated 1.5 million people are now using weight loss jabs through the NHS or private clinics, while millions more are eligible. But some experts have raised concerns over potential risks. Recent data revealed that more than 100 deaths in Britain have been linked to slimming injections so far. At least ten patients are confirmed to have died from pancreatitis—a life-threatening inflammation of the pancreas—after taking the jabs. The Medicines and Healthcare products Regulatory Agency (MHRA) has since launched an investigation into whether people with certain genes may be more vulnerable to the condition. It also follows recent reports of terrifying mental health side effects after women took the weight loss jab Mounjaro. Some described sudden panic attacks, crippling anxiety and a sensation of 'tugging in the brain' after starting the drug. Other reported symptoms included insomnia, tremors, shortness of breath and tinnitus. Although these are not currently listed as official side effects for any of the three major jabs in the UK, an online support group for users suffering such symptoms has attracted more than 2,800 members. Three members—speaking anonymously to The Times—described the onset of debilitating anxiety, sleeplessness and panic attacks after starting Mounjaro. At the time, the manufacturers of Mounjaro, Eli Lilly, and of both Ozempic and Wegovy, Novo Nordisk told The Times patient safety was their top priority. 'We take any reports about patient safety seriously and actively monitor, evaluate and report safety information for all our medicines,' said Eli Lilly. With Novo Nordisk adding it welcomes: 'Independent research investigating the safety, efficacy and clinical utility of our products.'
